| pubmed-article:10965209 | pubmed:abstractText | To reduce the time to monitor success of growth hormone therapy, Gulliver G-100 (G-100), a new portable height measurement device based on ultrasound technology, was developed and compared with a conventional determination system, the Harpenden stadiometer (HS). In addition, growth of 12 children was monitored at home twice per day 3 months before and 3 months during GH therapy. Mean body height of 101 children was 144.67 cm using G-100 compared to 145.16 cm using HS. The coefficient of variability of 3 measurements from each patient was 0.29 and 0.18 using G-100 or HS, respectively. Statistic analysis of these data revealed no significant difference between G- 100 or HS. Statistical analysis of short-time growth of 12 patients revealed an increase of growth velocity for 8 patients (p < 0.01) after 3 months. Calculated growth velocity using data revealed from short-time growth analysis with G-100 and using long-term growth analysis with HS did not show any significant difference. Our data reveal that G-100 is able to produce accurate results in height measurement comparable to the HS. Using G-100, the patient can be classified as a 'responder' of GH therapy already after 3 months. | lld:pubmed |
